BRAIN-SPINE INTERFACES TO REVERSE UPPER- AND LOWER-LIMB PARALYSIS
Developing fully-implantable brain-spine interfaces to restore movement in individuals with chronic paralysis through advanced neurosensors and neurostimulation systems.
Projectdetails
Introduction
A spinal cord injury (SCI) alters the communication between the brain and spinal cord. The consequences are dramatic impairments of upper-limb and lower-limb motor functions, which have a profound impact on the affected person, their family, and society. Currently, there are no approved therapies for SCI.
Economic Impact
The resulting costs of care amount to more than 2.5 million euros over the lifetime of a person with SCI.
Development of Brain-Spine Interfaces
Two ERCs combined with two ERC-PoCs enabled us to prototype two brain-spine interfaces (BSIs) that link the intended movements decoded from motor cortex activity to precise electrical stimulations of the spinal cord to promote these movements.
Achievements
These BSIs restored walking and arm/hand movements in nonhuman primate models of SCI, and as we report here, enabled one patient with chronic paralysis to walk again outdoors.
Limitations of Current Prototypes
These prototypes were partly based on repurposed devices that were not optimized for the intended applications, and thus presented shortcomings.
Proposed Solution
Here, we propose to integrate two breakthrough technologies to develop two fully-implantable BSIs that will remedy these limitations.
Technologies Involved
- The first technology consists of the only existing fully-implantable neurosensor for wireless monitoring of cortical activity in humans based on high-density grids positioned over the dura mater.
- The second technology is the only implantable neurostimulation system dedicated to the recovery of movement after paralysis. This system combines:
- An implantable pulse generator that enables highly reliable, real-time control of spinal cord stimulation.
- A portfolio of electrode arrays that have been designed to leverage the mechanisms through which this stimulation restores movement.
Clinical Trials
Two small-scale clinical trials will demonstrate that these BSIs restore lower-limb and upper-limb movements in humans with chronic paralysis.
Future Implications
These studies will provide specifications for industrial versions of the BSIs, opening the path to a commercially viable revolution for people living with paralysis.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.490.802 |
Totale projectbegroting | € 2.490.802 |
Tijdlijn
Startdatum | 1-5-2022 |
Einddatum | 30-4-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ONWARD MEDICAL NVpenvoerder
- COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
- DTS PATENT- UND RECHTSANWALTE PARTMBB
- STICHTING SINT MAARTENSKLINIEK
- ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
- ONWARD Medical SA
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Auto-adaptive Neuromorphic Brain Machine Interface: toward fully embedded neuroprostheticsThe NEMO BMI project aims to develop an assistance-free, user-friendly neuroprosthetic system that utilizes brain signals for limb control, enhancing usability and portability through innovative technologies. | EIC Pathfinder | € 3.784.703 | 2022 | Details |
A Direct Sensorimotor Connection with the Spared Neural Code of Movement to Regain Motor FunctionThis project aims to develop a bidirectional neural interface that enhances motor function in paralyzed individuals by precisely mapping and engaging spinal motor neurons through advanced sensing and feedback methods. | ERC STG | € 1.495.271 | 2024 | Details |
Mapping the brain-spinal cord interaction towards understanding and treatment of movement disordersMove2Treat aims to develop a novel bi-directional brain-spinal cord interface to enhance understanding and treatment of movement disorders through advanced neuronal circuit mapping. | EIC Pathfinder | € 2.996.048 | 2024 | Details |
Restoring movement lost to strokeThis project aims to develop a brain-spine interface to restore hand and arm movements in subcortical stroke survivors, potentially becoming the first effective treatment for their paralysis. | EIC Pathfinder | € 2.995.448 | 2025 | Details |
Auto-adaptive Neuromorphic Brain Machine Interface: toward fully embedded neuroprosthetics
The NEMO BMI project aims to develop an assistance-free, user-friendly neuroprosthetic system that utilizes brain signals for limb control, enhancing usability and portability through innovative technologies.
A Direct Sensorimotor Connection with the Spared Neural Code of Movement to Regain Motor Function
This project aims to develop a bidirectional neural interface that enhances motor function in paralyzed individuals by precisely mapping and engaging spinal motor neurons through advanced sensing and feedback methods.
Mapping the brain-spinal cord interaction towards understanding and treatment of movement disorders
Move2Treat aims to develop a novel bi-directional brain-spinal cord interface to enhance understanding and treatment of movement disorders through advanced neuronal circuit mapping.
Restoring movement lost to stroke
This project aims to develop a brain-spine interface to restore hand and arm movements in subcortical stroke survivors, potentially becoming the first effective treatment for their paralysis.